Peripheral arterial disease: Considerations in risks, diagnosis, and treatment

Journal of the National Medical Association

Volumn 101, Issue 10, 2009, Pages 999-1008

  Mukherjee, Debabrata ^a   Cho, Leslie ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTOXIFYLLINE; PLACEBO; RAMIPRIL; TELMISARTAN;

ACUTE CORONARY SYNDROME; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; HEALTH CARE QUALITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SMOKING CESSATION; THROMBOSIS;

ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; COMORBIDITY; HUMANS; HYPERTENSION; LIFE STYLE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 71049160844     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31066-X     Document Type: Article

References (57)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608-1621. (Pubitemid 32479915)
2. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645-658.
3. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1-S296.
4. Dieter RS, Biring T, Tomasson J, et al. Classic intermittent claudication is an uncommon manifestation of lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Angiology. 2004;55:625-628. (Pubitemid 39551958)
5. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738-743.
6. Meijer WT, Grobbee DE, Hunink MGM, et al. Determinants of peripheral arterial disease in the elderly: The Rotterdam study. Arch Intern Med. 2000;160:2934-2938. (Pubitemid 32009050)
7. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510-515. (Pubitemid 15133809)
8. Bertomeu V, Morillas P, Gonzalez-Juanatey JR, et al. Prevalence and prognostic influence of peripheral arterial disease in patients ≥40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg. 2008;36:189-196. (Pubitemid 351965492)
9. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324. (Pubitemid 33015522)
10. Ostchega Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55:583-589.
11. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci. 2002;57:M45-M46. (Pubitemid 34074445)
12. Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257-1264.
13. Levy PJ. Epidemiology and pathophysiology of peripheral arterial disease. Clin Cornerstone. 2002;4:1-15.
14. Becker GJ, McClenny TE, Kovacs ME, et al. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol. 2002;13:7-11.
15. Hayoz D, Bounameaux H, Canova CR. Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease. J Intern Med. 2005;258:238-243. (Pubitemid 41243055)
16. Feringa HH, Bax JJ, van Waning VH, et al. The long-term prognostic value of the resting and postexercise ankle-brachial index. Arch Intern Med. 2006;166:529-535.
17. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease: a national clinical guideline. http://www.sign.ac. uk. Accessed September 15, 2008.
18. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241-245.
19. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
20. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAHantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47:1239-1312.
21. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94:3026-3049. (Pubitemid 26411793)
22. Dieter RS, Chu WW, Pacanowski JP Jr, et al. The significance of lower extremity peripheral arterial disease. Clin Cardiol. 2002;25:3-10. (Pubitemid 34049124)
23. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ. 2000;320:1262-1265.
24. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
25. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha-4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
26. US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline). http://www.fda.gov/cder/drug/advisory/ varenicline.htm. Accessed May 16, 2008.
27. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433-1437. (Pubitemid 33716433)
28. Gonzalez-Clemente JM, Pinies JA, Calle-Pascual A, et al. Cardiovascular risk factor management is poorer in diabetic patients with undiagnosed peripheral arterial disease than in those with known coronary heart disease or cerebrovascular disease. Results of a nationwide study in tertiary diabetes centres. Diabet Med. 2008;25:427-434.
29. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(1)(suppl):S4-S36.
30. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
31. Ahimastos AA, Dart AM, Lawler A, et al. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens. 2008;26:1037-1042.
32. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
34. Spring S, Simon R, van der Loo B, et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost. 2008;99:182-189.
35. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
36. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
37. Dey S, Mukherjee D. Clinical perspectives on the role of anti-platelet and statin therapy in patients with vascular diseases. Curr Vasc Pharmacol. 2003;1:329-333.
38. Mukherjee D, Dey S, Ungam P. Predictors of clinical outcomes in patients undergoing peripheral vascular interventions: Insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Iniative (PVD-Q12). Abstract # 1199-2175 J Am Coll Cardiol. 2003;(suppl 1):75A.
39. Chen ZM, Jiang LX, Chen YP, et al. Addition of Clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
40. Yusuf S, Zhao F, Mehta SR, et al. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
41. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. (Pubitemid 40397259)
42. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
43. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
44. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148:263-268.
45. Bhatt DL, Fox KA, Hacke W, et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2005;150:401.
46. Spertus J, Jones P, Poler S, et al. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004;147:301-308. (Pubitemid 38180531)
47. Santilli JD, Santilli SM. Chronic critical limb ischemia: diagnosis, treatment and prognosis. Am Fam Physician. 1999;59:1899-1908. (Pubitemid 29169723)
48. Nehler MR, Hiatt WR. Exercise therapy for claudication. Ann Vasc Surg. 1999;13:109-114.
49. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107:757-761. (Pubitemid 36222606)
50. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163:884-892. (Pubitemid 36519734)
51. Mousa AY, Beauford RB, Flores L, et al. Endovascular treatment of iliac occlusive disease: review and update. Vascular. 2007;15:5-11. (Pubitemid 46797750)
52. Imparato AM, Kim GE, Davidson T, et al. Intermittent claudication: its natural course. Surgery. 1975;78:795-799.
53. McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209-215. (Pubitemid 27175894)
54. McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med. 2002;17:895-904. (Pubitemid 35471987)
55. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation. 2002;106:1909-1912. (Pubitemid 35176293)
56. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203-209. (Pubitemid 38140408)
57. Mukherjee D, Munir K, Hirsch AT, et al. Development of a multicenter peripheral arterial interventional database: the PVD-QI2. Am Heart J. 2005;149:1003-1008. (Pubitemid 40848144)